ClinicalTrials.gg
RecruitingNCT07214064Updated Nov 12, 2026

Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation

A Phase 2 interventional study of RIC regimen in AML (Acute Myeloid Leukemia), MDS/AML and MDS (Myelodysplastic Syndrome), sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University Hospital Tuebingen · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 12, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 281 studies in Leukemia, Myeloid, Acute with a site in Germany — 32 open to participants now, 54 under way, 18 of them phase 3. Leukemia, Myeloid, Acute · Germany.

Planned enrollment
217th of 261
27 · median 126
Started
2026
with 5 others
Phase 2
72 of 281
7 open now
Primary completion
2027-08
later than 27 of 53 live
Registered
278th of 281
by date

Among the 281 studies in Leukemia, Myeloid, Acute with a site in Germany, this one is the 217th largest by planned enrollment of the 261 interventional ones that give a count, is one of 6 that started in 2026, is one of 72 in phase 2, reaches primary completion later than 27 of the 53 other live ones, and was the 278th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

32 of the 281 studies in Leukemia, Myeloid, Acute with a site in Germany are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 281 studies in Leukemia, Myeloid, Acute with a site in Germany, or all of them as a file.
02

Study summary

Safety and Feasibility of a Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation in AML, MDS/AML and Higher Risk MDS

03

Conditions studied

  • AML (Acute Myeloid Leukemia)
  • MDS/AML
  • MDS (Myelodysplastic Syndrome)

Keywords

  • Allogeneic Stem Cell Transplantation
  • Venetoclax
  • Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning
  • RIC
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 75 years at the time of signing the
  2. Patient is fluent in German
  3. Signed written Informed Consent with the cognitive ability to understand all consequences of trial participation and to comply with all trial related procedures
  4. Diagnosis of AML,MDS/AML (according to ICC 2022) or HRMDS (IPSS-R7 >3.5 or IPSS-M8 >0; according to ICC 20226 and IWG 2023)
  5. Myeloid neoplasm (AML, MDS/AML or HR-MDS according to ICC 2022) under control* at time of screening, defined as one of the following:

    5.1. AML (ICC 2022):

    • Scheduled for alloHCT after prior Remission

    Induction ± Consolidation:

    • Achievement of at least MLFS** (according to ELN 2022 criteria) after up to two cycles of intensive, anthracycline-based induction chemotherapy OR
    • Achievement of at least MLFS** (according to ELN 2022 criteria) after intensive, anthracycline-based induction chemotherapy folllowed by up to three cycles of cytostatic consolidation therapy OR
    • Achievement of at least MLFS** (according to ELN 2022) after less intensive, HMA-based treatment (up to six cycles) OR
    • Achievement of at least MLFS** (according to ELN 2022) after a combination of intensive and less intensive treatments (up to six cycles in total) 5.2. MDS/AML (ICC 2022):• Scheduled for alloHCT after prior Remission

    Induction ± Consolidation:

    • Achievement of at least MLFS** (according to ELN 2022 criteria) after up to two cycles of intensive, anthracycline-based induction chemotherapy OR
    • Achievement of at least MLFS** (according to ELN 2022 criteria), after intensive, anthracycline-based induction chemotherapy folllowed by up to three cycles of cytostatic consolidation therapy OR
    • Achievement of at least MLFS** (according to ELN 2022 criteria) after less intensive, HMA-based treatment*** (up to six cycles and including HMA monotherapy) OR
    • Achievement of at least MLFS (according to ELN 2022 criteria) after a combination of intensive and less intensive treatments (up to six cycles in total)
    • Scheduled for upfront alloHCT***:
    • ≤19% bone marrow blastsAND• ≤19% peripheral blood blastsAND• ≤15.000/µl peripheral blood Leukocytes 5.3. HR- MDS (ICC 2022, IWG 2023)
    • Scheduled for alloHCT after prior therapy***:
    • up to six cycles of a less intensive HMAbased treatment or HMA monotherapy AND
    • ≤9% bone marrow blastsAND• ≤9% peripheral blood blasts
    • Scheduled for upfront alloHCT***:
    • ≤9% bone marrow blasts AND
    • ≤9% peripheral blood blasts

      • The disease is considered clinically controlled, when it is either aggressive but has proven responsive to cytostatic chemotherapy (e.g. AML with achievement of at least MLFS) or slowly progressive ( e.g. suitable for upfront alloHCT in cases of MDS/AML) or is both slowly progressive and responsive to therapy **a bone marrow assessment is mandatory during screening phase. Patients canonly be enrolled after the according inclusion criteria have been confirmed bybone marrow . The time window for bone marrow biopsy is day -21 to -14.

        • pretreatment with Erythropoesis-Stimulating Factors, Inhibitors of TGF-β-Signalling or Lenalidomid is permitted in patients scheduled for upfront , as well as in patients after HMA-based therapy
  6. Eligiblity for alloHCT according to a board of experienced haematologists
  7. Performance Index ≥60%
  8. Planned alloHCT with Peripheral Blood Stem Cells (PBSC)
  9. Infusion of allogeneic stem cells schedulded between day 14 and day 28 after Screening
  10. Availability of a suitable donor, defind as one of the following:

    10.1. HLA-identical sibling (MSD)OR 10.2. HLA-compatible (9/10 antigens matched for HLA-A, -B, -C, -DRB1, and -DQB1) unrelated donor (MUD) with completed confirmatory typing.

    OR 10.3. Two unrelated donors with >90% probability of a 9/10 match for HLA- A, -B, -C, -DRB1, and -DRQB1, according to OptiMatch list (MUD)

  11. Documented diffusion lung capacity for carbon monoxide (DLCO) >40% (adjusted for , if available) and /FVC >50%
  12. (LVEF) ≥40%
  13. (CKD-EPI) ≥ 30 ml/min/1,73 m2
  14. ≤3x and ≤5x ULN
  15. Thoracic imaging (either X-ray or computed tomography (CT)) without evidence of active infection or second
  16. Subject (male or female) is willing to use highly effective methods during treatment and for 6 months (male or female) after the end of treatment (adequate: combined hormonal associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner1, sexual abstinence2). Female participants using homonal contraceptives should use a barrier method as well.1 Vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of the FCBP trial participant and that the vasectomized partner has received medical assessment of the surgical success2 In the context of this guidance sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.
  17. Absence of pregnancy confirmed by a highly sensitive pregnancy test not older than 3 days at time of screening (only FCBP).
  18. Subject agrees not to share medication.

Exclusion criteria

Exclusion Criteria:

  1. APL (AML with t(15;17))
  2. MDS/MPN (ICC 20226)
  3. Performance Index \<60%
  4. Patient scheduled for haploidentical allogeneic hematopoetic stem cell transplantation or bone marrow stem cell transplantation
  5. Presence of extramedullary myelosarcoma
  6. Disease Relapse after prior CRc
  7. History of hematopoietic stem cell transplantation
  8. Significant active cardiac disease within 6 months prior to the start of study treatment, including:

    • (NYHA) class III or IV congestive heart failure
    • Myocardial infarction
    • Unstable angina
    • Cerebral apoplexy
    • Severe cardiac arrhythmias
    • (LVEF) \<40% by TTE
  9. Documented diffusion lung capacity for carbon monoxide (DLCO) ≤40% (adjusted for , if available) and /FVC ≤50%
  10. (CKD-EPI) \<30 ml/min/1,73 m2
  11. >3x or >5x ULN
  12. Clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia.
  13. Active viral infection, including , or (HIV) infection, that is uncontrolled prior to first dose of study treatment and may interfere with the study objectives or which could expose the patient to undue risk through the participation in the clinical trial. An infection controlled with an approved antiviral treatment is allowed.
  14. Presence of Proven, Probable or Possible Invasive Fungal Disease (IFD) as defined by EORTC/MSG 20209 Definitions (please consult Appendix)
  15. Serologies suggestive of recent (\<6 months) infection or reactivation with/of Toxoplasma gondii (based on IgG, IgM and Avidity) or of infection with Treponema pallidum (based on TPPA).
  16. Any clinically uncontrolled infection (bacterial or unknown pathogen), defined as persisting or recurring fever or rising levels of CRP (≥10 mg/dl) despite intravenous antibacterial or antifungal therapy (initiated or escalated at least 72h hours ago)
  17. Immediate life-threatening, severe complications of leukemia such as uncontrolled bleeding and/or disseminated intravascular coagulation.
  18. Conditions that limit the ingestion or gastrointestinal absorption of orally administered drugs.
  19. Patients with a currently active second . Patients are not considered to have a currently active malignancy, if they have completed therapy and are considered by their physician to be at \<30% risk of relapse within one year. However, patients with the following history/concurrent conditions are allowed:

    • Basal or squamous cell carcinoma of the skin;
    • Carcinoma in situ of the cervix;
    • Carcinoma in situ of the breast;
    • Incidental histologic finding of prostate cancer.
  20. Receipt of live, attenuated vaccine within 30 days prior to the study inclusion (NOTE: patients, if enrolled, should not receive during the study and until 6 months after the therapy)
  21. Severe neurological or psychiatric disorder interfering with ability to give an .
  22. Women during pregnancy and lactation.
  23. History of to the medicinal product or to any drug with similar chemical structure or to any present in the pharmaceutical form of the investigational medicinal product.
  24. Participation in other trials interfering with the endpoint of this study. Prior trial participation is permitted, provided that treatment with the investigational medicinal product has been completed at least 4 days prior to screening for this trial (at least 10 days before planned study treatment).
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Reduced Intensity Conditioning before Allogeneic Stem Cell Transplantation

    Patients with AML, MDS/AML or HR-MDS, who have either responded to remission inducing therapy or are intended for upfront transplantion receive conditioning chemotherapy as follows: IMPs: * Venetoclax 400 mg abs. day -8 to day -2 * Fludarabine 30 mg/m2 BSA day -6 to day -2 * Treosulfan 10 g/m2 BSA day -4 to day -2

    Drug: RIC regimen

Interventions

  • DrugRIC regimen

    Venetoclax (Venclyxto®): 400 mg abs./d day -8 to -2, Fludarabine 30 mg/m2 BSA day -6 to day -2, Treosulfan 10 g/m2 BSA day -4 to day -2

06

What researchers measure

Primary outcomes

  1. Treatment-Related Mortality (TRM) at day 28 after alloHCT

    Primary objective of this trial is to evaluate the feasibility and safety of the augmentation of a treosulfanbased RIC regimen for alloHCT in AML, MDS/AML and HR-MDS patients with the Bcl-2-inhibitor Venetoclax. As outlined above, the aim is to increase antileukemic acitiviy without increasing morbidity and mortality in a vulnerable patient collective. This is operationalized by the following primary endpoint: 1\) Treatment-Related Mortality (TRM) at day 28 after alloHCT Most adverse events (AEs) due to the IMPs are expected to occur before day 0. Protacted or lateonset toxicities with potentially lethal consequences cannot be ruled out. Therefore, we regard it most suitable to evaluate TRM at day 28 after alloHCT.

    Time frame: at day 28 after alloHCT

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Aug 2027, 18 months after the start.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 18 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Feb 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Oct 9, 2025
StartActual
Feb 19, 2026was Jan 2026
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
University Hospital , Department of Internal Medicine II is now Recruiting
Nov 12, 2026
Start date
Jan 2026→Feb 19, 2026 (actual)
Nov 12, 2026
Eligibility
15 inclusion criteria edited, 4 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedDiagnosis of AML,MDS/AML (according to ICC 202262022) or HRMDS (IPSS-R7 >3.5 or IPSS-M8 >0; according to ICC 20226 and IWG 202322023)
  • EditedMyeloid neoplasm (AML, MDS/AML or HR-MDS according to ICC 202262022) under control* at time of screening, defined as one of the following:
  • Edited5.1. AML (ICC 202262022):
  • EditedAchievement of at least MLFS** (according to ELN 202212022 criteria) after up to two cycles of intensive, anthracycline-based induction chemotherapy OR
  • EditedAchievement of at least MLFS** (according to ELN 202212022 criteria) after intensive, anthracycline-based induction chemotherapy folllowed by up to three cycles of cytostatic consolidation therapy OR
  • EditedAchievement of at least MLFS** (according to ELN 202212022) after less intensive, HMA-based treatment (up to six cycles) OR
  • EditedAchievement of at least MLFS** (according to ELN 202212022) after a combination of intensive and less intensive treatments (up to six cycles in total) 5.2. MDS/AML (ICC 202262022):• Scheduled for alloHCT after prior Remission
  • EditedAchievement of at least MLFS** (according to ELN 202212022 criteria) after up to two cycles of intensive, anthracycline-based induction chemotherapy OR
  • EditedAchievement of at least MLFS** (according to ELN 202212022 criteria), after intensive, anthracycline-based induction chemotherapy folllowed by up to three cycles of cytostatic consolidation therapy OR
  • EditedAchievement of at least MLFS** (according to ELN 202212022 criteria) after less intensive, HMA-based treatment*** (up to six cycles and including HMA monotherapy) OR
  • EditedAchievement of at least MLFS (according to ELN 202212022 criteria) after a combination of intensive and less intensive treatments (up to six cycles in total)• Scheduled for upfront alloHCT:
  • AddedScheduled for upfront alloHCT***:
  • Edited≤19% bone marrow blastsAND• ≤19% peripheral blood blastsAND• ≤15.000/µl peripheral blood Leukocytes 5.3. HR- MDS (ICC 202262022, IWG 202322023)
  • EditedScheduled for alloHCT after prior therapy***:
  • Edited≤9% bone marrow blastsAND• ≤9% peripheral blood blasts• Scheduled for upfront alloHCT:
  • AddedScheduled for upfront alloHCT***:
  • Added≤9% peripheral blood blasts
  • Edited≤9% peripheral blood blasts *The disease is considered clinically controlled, when it is either aggressive but has proven responsive to cytostatic chemotherapy (e.g. AML with achievement of at least MLFS) or slowly progressive ( e.g. suitable for upfront alloHCT in cases of MDS/AML) or is both slowly progressive and responsive to therapy **a bone marrow assessment is mandatory during screening phase. Patients canonly be enrolled after the according inclusion criteria have been confirmed bybone marrow biopsy. The time window for bone marrow biopsy is day -21 to -14.
  • Removeda bone marrow assessment is mandatory during screening phase. Patients canonly be enrolled after the according inclusion criteria have been confirmed bybone marrow biopsy. The time window for bone marrow biopsy is day -21 to -14.
  • Addedpretreatment with Erythropoesis-Stimulating Factors, Inhibitors of TGF-β-Signalling or Lenalidomid is permitted in patients scheduled for upfront alloHSCT, as well as in patients after HMA-based therapy
Nov 12, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Overall survival (OS)Now Treatment-Related Mortality (TRM) at day 28 after alloHCTTime frame: at day 28 after alloHCT
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    University Hospital , Department of Internal Medicine II is now Recruiting
    Start date Jan 2026→Feb 19, 2026 (now actual)
    Eligibility 15 inclusion criteria edited, 4 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedDiagnosis of AML,MDS/AML (according to ICC 202262022) or HRMDS (IPSS-R7 >3.5 or IPSS-M8 >0; according to ICC 20226 and IWG 202322023)
    • EditedMyeloid neoplasm (AML, MDS/AML or HR-MDS according to ICC 202262022) under control* at time of screening, defined as one of the following:
    • Edited5.1. AML (ICC 202262022):
    • EditedAchievement of at least MLFS** (according to ELN 202212022 criteria) after up to two cycles of intensive, anthracycline-based induction chemotherapy OR
    • EditedAchievement of at least MLFS** (according to ELN 202212022 criteria) after intensive, anthracycline-based induction chemotherapy folllowed by up to three cycles of cytostatic consolidation therapy OR
    • EditedAchievement of at least MLFS** (according to ELN 202212022) after less intensive, HMA-based treatment (up to six cycles) OR
    • EditedAchievement of at least MLFS** (according to ELN 202212022) after a combination of intensive and less intensive treatments (up to six cycles in total) 5.2. MDS/AML (ICC 202262022):• Scheduled for alloHCT after prior Remission
    • EditedAchievement of at least MLFS** (according to ELN 202212022 criteria) after up to two cycles of intensive, anthracycline-based induction chemotherapy OR
    • EditedAchievement of at least MLFS** (according to ELN 202212022 criteria), after intensive, anthracycline-based induction chemotherapy folllowed by up to three cycles of cytostatic consolidation therapy OR
    • EditedAchievement of at least MLFS** (according to ELN 202212022 criteria) after less intensive, HMA-based treatment*** (up to six cycles and including HMA monotherapy) OR
    • EditedAchievement of at least MLFS (according to ELN 202212022 criteria) after a combination of intensive and less intensive treatments (up to six cycles in total)• Scheduled for upfront alloHCT:
    • AddedScheduled for upfront alloHCT***:
    • Edited≤19% bone marrow blastsAND• ≤19% peripheral blood blastsAND• ≤15.000/µl peripheral blood Leukocytes 5.3. HR- MDS (ICC 202262022, IWG 202322023)
    • EditedScheduled for alloHCT after prior therapy***:
    • Edited≤9% bone marrow blastsAND• ≤9% peripheral blood blasts• Scheduled for upfront alloHCT:
    • AddedScheduled for upfront alloHCT***:
    • Added≤9% peripheral blood blasts
    • Edited≤9% peripheral blood blasts *The disease is considered clinically controlled, when it is either aggressive but has proven responsive to cytostatic chemotherapy (e.g. AML with achievement of at least MLFS) or slowly progressive ( e.g. suitable for upfront alloHCT in cases of MDS/AML) or is both slowly progressive and responsive to therapy **a bone marrow assessment is mandatory during screening phase. Patients canonly be enrolled after the according inclusion criteria have been confirmed bybone marrow biopsy. The time window for bone marrow biopsy is day -21 to -14.
    • Removeda bone marrow assessment is mandatory during screening phase. Patients canonly be enrolled after the according inclusion criteria have been confirmed bybone marrow biopsy. The time window for bone marrow biopsy is day -21 to -14.
    • Addedpretreatment with Erythropoesis-Stimulating Factors, Inhibitors of TGF-β-Signalling or Lenalidomid is permitted in patients scheduled for upfront alloHSCT, as well as in patients after HMA-based therapy
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Overall survival (OS)Now Treatment-Related Mortality (TRM) at day 28 after alloHCTTime frame: at day 28 after alloHCT
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07214064
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Feb 19, 2026
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Christoph Faul, Dr.
Contact
Christoph.Faul@med.uni-tuebingen.de
+49 7071 29-84087
Wolfgang Bethge, Prof. Dr.
Contact
Wolfgang.Bethge@med.uni-tuebingen.de
+49 7071 29-83176
Christoph Faul, Dr.
principal investigator · Sponsor's Delegate

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion